Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Nanobiotix in a report released on Friday, September 25th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.33) per share for the year, down from their prior forecast of $0.37. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.62) per share.
NBTX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Leerink Partners boosted their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, Guggenheim started coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nanobiotix presently has an average rating of “Moderate Buy” and an average price target of $46.67.
Nanobiotix Stock Performance
NBTX stock opened at $31.16 on Tuesday. The firm’s 50-day moving average price is $38.32 and its two-hundred day moving average price is $37.29. Nanobiotix has a 12-month low of $14.78 and a 12-month high of $57.14.
Nanobiotix Company Profile
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
Featured Articles
- Five stocks we like better than Nanobiotix
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
